Jansen type metaphyseal chondrodysplasia

From WikiMD's Food, Medicine & Wellness Encyclopedia

Alternate names[edit | edit source]

Metaphyseal chondrodysplasia Murk Jansen type; Murk Jansen type metaphyseal chondrodysplasia

Definition[edit | edit source]

Jansen's metaphyseal chondrodysplasia (JMC) is a very rare autosomal dominant skeletal dysplasia characterized by short-limbed short stature (due to severe metaphyseal changes that are often discovered in childhood by imaging), waddling gait, bowed legs, contracture deformities of the joints, short hands with clubbed fingers, clinodactyly, prominent upper face and small mandible, as well as chronic parathyroid hormone-independent hypercalcemia, hypercalciuria, and mild hypophosphatemia.

Cause[edit | edit source]

Five different heterozygous activating PTH/PTHrP receptor (PTH1R) mutations that change one of three different amino acid residues are known to cause JMC.[1]

Inheritance[edit | edit source]

Autosomal dominant pattern, a 50/50 chance.

It is found to be inherited in autosomal dominant manner.

Clinical presentation[edit | edit source]

  • Jansen's metaphyseal chondrodysplasia (JMC) is a rare skeletal dysplasia characterized by abnormal endochondral bone formation and typically severe hypercalcemia despite normal/low levels of PTH.[2]
  • The limbs of affected individuals typically show progressive postnatal changes that are caused by an abnormal regulation of chondrocyte growth and differentiation, eventually leading to short and bowed legs.
  • JMC is typically associated with severe and, generally, asymptomatic hypercalcemia and hypophosphatemia, with low-normal or undetectable serum PTH levels.

Diagnosis[edit | edit source]

  • Sclerosis of the skull base, an unusual finding in other skeletal dysplasias along with rickets-like metaphyseal changes, helped establish the diagnosis during infancy.
  • However, the H223R mutation did not cause overt hypercalcemia in the affected mother and has been a confounding factor in establishing the diagnosis.[3]

Treatment[edit | edit source]

There is no known treatment at present, although some investigators have tried to lessen the hypercalcemia with various forms of bisphosphonates.


References[edit | edit source]

  1. Nampoothiri, Sheela et al. “Jansen Metaphyseal Chondrodysplasia due to Heterozygous H223R-PTH1R Mutations With or Without Overt Hypercalcemia.” The Journal of clinical endocrinology and metabolism vol. 101,11 (2016): 4283-4289. doi:10.1210/jc.2016-2054
  2. Nampoothiri, Sheela et al. “Jansen Metaphyseal Chondrodysplasia due to Heterozygous H223R-PTH1R Mutations With or Without Overt Hypercalcemia.” The Journal of clinical endocrinology and metabolism vol. 101,11 (2016): 4283-4289. doi:10.1210/jc.2016-2054
  3. Nampoothiri, Sheela et al. “Jansen Metaphyseal Chondrodysplasia due to Heterozygous H223R-PTH1R Mutations With or Without Overt Hypercalcemia.” The Journal of clinical endocrinology and metabolism vol. 101,11 (2016): 4283-4289. doi:10.1210/jc.2016-2054


NIH genetic and rare disease info[edit source]

Jansen type metaphyseal chondrodysplasia is a rare disease.


Jansen type metaphyseal chondrodysplasia Resources
Doctor showing form.jpg
Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Deepika vegiraju